December 8, 2025BloodOpen Access

Spectrum, molecular features, and clinical outcomes of hematologic malignancies and clonal hematopoiesis in li fraumeni syndrome

View Full Paper

Ask AI

Bookmark

Hematologic malignancies identified in 12.2% of Li Fraumeni syndrome patients, signifying significant risk.
Acute myeloid leukemia, chronic lymphocytic lymphoma, and T-prolymphocytic leukemia were among the types observed.
Analysis of clinical and molecular data from patients with TP53 variants revealed critical insights about disease progression.
Competing risks from non-hematologic cancers remain significant, necessitating continued LFS screening beyond hematologic malignancies.

Discussion

No takes yet. Share an insight, caveat, or question.

Retrospective analysis found 12% of Li Fraumeni syndrome patients develop hematologic malignancies, highlighting genetic implications.

Kennedy et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark